Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 4Terminated 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × padeliporfin × Clear all
NCT00975039 2016-04-18

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Steba Biotech S.A.

Phase 2 Terminated
8 enrolled
Gastrointestinal

Carcinoma, Cholangiocarcinoma

NCT00974662 2015-04-28

Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer

Steba Biotech S.A.

Phase 2 Terminated
3 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡